The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana

This study has been completed.
Sponsor:
Collaborator:
Hadassah Medical Organization
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00270803
First received: December 25, 2005
Last updated: May 6, 2008
Last verified: December 2005

December 25, 2005
May 6, 2008
July 2004
December 2005   (final data collection date for primary outcome measure)
Brain metabolic activity (FDG) [ Time Frame: 30-40 minutes ] [ Designated as safety issue: No ]
Brain metabolic activity (FDG)
Complete list of historical versions of study NCT00270803 on ClinicalTrials.gov Archive Site
  • Reaction time (RTs) and errors in performance [ Time Frame: 40 minutes ] [ Designated as safety issue: No ]
  • Subjective ratings on visual analog scale [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
  • Reaction time (RTs) and errors in performance
  • Subjective ratings on visual analog scale
Not Provided
Not Provided
 
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana.

This study investigates the effects of 17mg and 13mg Delta THC on orientation and motor coordination and brain metabolic activity in regular users of marijuana. Subjects were tested twice, after smoking cigarettes with marijuana and after smoking cigarettes without marijuana.On both occasions they performed on a virtual reality maze task. They were afterwards scanned in Positron Emission Tomography (PET) with Fluoro-deoxy-glucose (FDG).

This study investigates the effects of 17mg and 13mg Delta THC on orientation and motor coordination and brain metabolic activity in regular users of marijuana. Subjects were tested twice, after smoking cigarettes with marijuana and after smoking cigarettes without marijuana. On both occasions they performed on a virtual reality maze task. They were afterwards scanned in Positron Emission Tomography (PET) with Fluoro-deoxy-glucose (FDG). 12 subjects were tested so far on both conditions.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Marijuana Dependence
Drug: Tetra Hydro Cannabinol (THC)
Oral THC 13mg and 17mg smoked in low nicotine cigarettes
Other Name: Marijuana, cannabis
Placebo Comparator: A
Low nicotine cigarettes without THC
Intervention: Drug: Tetra Hydro Cannabinol (THC)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
December 2005
December 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Marijuana dependence
  • Age 20-65
  • Male and female

Exclusion Criteria:

  • Pregnant women
  • Dependence on other substances
  • Psychiatric diagnosis apart from marijuana dependence
  • Neurological disorder
  • Young persons
Both
20 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00270803
TASMC-05-EE-03-124-CTIL
No
Dr. Michal Roll, Sourasky Medical Center Tel Aviv
Tel-Aviv Sourasky Medical Center
Hadassah Medical Organization
Principal Investigator: Aviv M Weinstein, Ph.D Sourasky Medical Center
Principal Investigator: Einat Even-Sapir, M.D. Ph.D Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP